These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16116136)

  • 1. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil.
    Vernino S; Salomao DR; Habermann TM; O'Neill BP
    Neurology; 2005 Aug; 65(4):639-41. PubMed ID: 16116136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell lymphoproliferative disorder following mycophenolate treatment for myasthenia gravis.
    Dubal DB; Mueller S; Ruben BS; Engstrom JW; Josephson SA
    Muscle Nerve; 2009 Jun; 39(6):849-50. PubMed ID: 19358236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma.
    Gajra A; Vajpayee N; Grethlein SJ
    Am J Hematol; 2004 Oct; 77(2):196-7. PubMed ID: 15389902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab.
    Hain B; Jordan K; Deschauer M; Zierz S
    Muscle Nerve; 2006 Apr; 33(4):575-80. PubMed ID: 16323216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil in the therapy of severe myasthenia gravis.
    Schneider C; Gold R; Reiners K; Toyka KV
    Eur Neurol; 2001; 46(2):79-82. PubMed ID: 11528156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The muddle of mycophenolate mofetil in myasthenia.
    Benatar M; Rowland LP
    Neurology; 2008 Aug; 71(6):390-1. PubMed ID: 18678821
    [No Abstract]   [Full Text] [Related]  

  • 7. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.
    Meriggioli MN; Ciafaloni E; Al-Hayk KA; Rowin J; Tucker-Lipscomb B; Massey JM; Sanders DB
    Neurology; 2003 Nov; 61(10):1438-40. PubMed ID: 14638974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myasthenia gravis: emerging new therapy options.
    Sieb JP
    Curr Opin Pharmacol; 2005 Jun; 5(3):303-7. PubMed ID: 15907918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil - as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: The Singapore experience.
    Prakash KM; Ratnagopal P; Puvanendran K; Lo YL
    J Clin Neurosci; 2007 Mar; 14(3):278-81. PubMed ID: 16597503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis.
    Adams B; Lazarchick J; Medina AM; Willner IR; Neville B; Murphy E; Stuart R; Costa LJ
    Am J Hematol; 2010 Aug; 85(8):627-9. PubMed ID: 20658594
    [No Abstract]   [Full Text] [Related]  

  • 11. Mycophenolate mofetil treatment of myasthenia gravis.
    Cahoon WD; Kockler DR
    Ann Pharmacother; 2006 Feb; 40(2):295-8. PubMed ID: 16403848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis.
    Muscle Study Group
    Neurology; 2008 Aug; 71(6):394-9. PubMed ID: 18434639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of severe myasthenia gravis developed after allogeneic hematopoietic stem cell transplantation with plasma exchange and rituximab.
    Unal S; Sag E; Kuskonmaz B; Kesici S; Bayrakci B; Ayvaz DC; Tezcan I; Yalnızoglu D; Uckan D
    Pediatr Blood Cancer; 2014 May; 61(5):928-30. PubMed ID: 24307660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis.
    Mowzoon N; Sussman A; Bradley WG
    J Neurol Sci; 2001 Apr; 185(2):119-22. PubMed ID: 11311292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil treatment in dogs with serologically diagnosed acquired myasthenia gravis: 27 cases (1999-2008).
    Dewey CW; Cerda-Gonzalez S; Fletcher DJ; Harb-Hauser MF; Levine JM; Badgley BL; Olby NJ; Shelton GD
    J Am Vet Med Assoc; 2010 Mar; 236(6):664-8. PubMed ID: 20225980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.
    Sanders DB; Hart IK; Mantegazza R; Shukla SS; Siddiqi ZA; De Baets MH; Melms A; Nicolle MW; Solomons N; Richman DP
    Neurology; 2008 Aug; 71(6):400-6. PubMed ID: 18434638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of myasthenia gravis with mycophenolate mofetil: a case report.
    Meriggioli MN; Rowin J
    Muscle Nerve; 2000 Aug; 23(8):1287-9. PubMed ID: 10918271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depressive disorder associated with mycophenolate mofetil.
    Draper HM
    Pharmacotherapy; 2008 Jan; 28(1):136-9. PubMed ID: 18154484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil in myasthenia gravis: the unanswered question.
    Phan C; Sanders DB; Siddiqi ZA
    Expert Opin Pharmacother; 2008 Oct; 9(14):2545-51. PubMed ID: 18778192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity.
    Lim AK; Donnan G; Chambers B; Ierino FL
    Intern Med J; 2007 Jan; 37(1):55-9. PubMed ID: 17199845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.